Industry news

• Novel nanoemulsion-based delivery of antimycobacterial drug

  31 October 2024 Catherine Eckford / European Pharmaceutical Review

  The manufacturing process for the nanoemulsion could be adapted for industrial-scale production, the researchers suggested. A paper has a described the first reported use of nanoemulsions as a novel delivery vehicle for the oral drug bedaquline (BDQ) “with high loading efficiency as a liquid dosage form”, according to the authors. 

• Russia will create a National Center for Genetic Resources of Microorganisms

  31 October 2024 GxP news

  Russian President Vladimir Putin has enacted a decree to establish the National Center for Genetic Resources of Microorganisms, which will be based at the National Research Center Kurchatov Institute.

• Optimising drug release of personalised 3D printed tablets

  30 October 2024 Catherine Eckford / European Pharmaceutical Review

  The 3D printing study enabled a precise tablet structure to be created, allowing for easy modification and for the control of drug release rate through changing the surface curvature.

• Immunotherapy treatment enhances lymphoma survival, landmark study shows

  30 October 2024

  The Phase III findings give evidence for the immunotherapy treatment regimen to become standard of care for advanced Hodgkin lymphoma. A new immunotherapy treatment regimen (nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD)) provided a significant survival rate in advanced Hodgkin lymphoma patients, Phase III trial data shows.

• St. Petersburg Chemical and Pharmaceutical University will begin producing its own medicines

  29 October 2024 GxP news

  Saint Petersburg State Chemical Pharmaceutical University plans mass production of three innovative drugs based on original molecular compounds. Information about this was provided by Sergey Okovity, head of the Department of Pharmacology and Clinical Pharmacology. Currently, the institution is in discussions with five prominent domestic pharmaceutical manufacturers regarding collaborative funding for the second and third phases of clinical trials, as well as establishing the production process.

• Trial highlights potential next-gen biologic for lung cancer

  29 October 2024 Catherine Eckford / European Pharmaceutical Review

  Preliminary results from an ongoing trial of a novel monoclonal antibody have confirmed favourable efficacy and safety in recurrent extensive-stage small cell lung cancer (SCLC).

• Drug combination shows promise for mitigating microbial biofilms

  28 October 2024 Catherine Eckford / European Pharmaceutical Review

  Combining allicin with domiphen could reduce biofilm formation, providing a potential avenue for overcoming antimicrobial resistance, research suggests.

• Over two years, Moscow supported 100 projects for clinical trials of drugs

  28 October 2024 GxP news

  Saint Petersburg State Chemical Pharmaceutical University plans mass production of three innovative drugs based on original molecular compounds. Information about this was provided by Sergey Okovity, head of the Department of Pharmacology and Clinical Pharmacology. Currently, the institution is in discussions with five prominent domestic pharmaceutical manufacturers regarding collaborative funding for the second and third phases of clinical trials, as well as establishing the production proc

  A special program in Moscow led to 100 clinical drug trial projects over two years, involving 23 Russian and foreign companies, according to Deputy Mayor Anastasia Rakova. She noted that the ecosystem established in the capital, centered around a communication hub, has effectively supported research across 15 therapeutic areas. As part of the program, a total of 36 studies focused on bioanalogs and generics, 50 studies dedicated to original drugs, and 14 studies oriented toward vaccines were initiated.

  ess.

• In 2023 Russia registered 56 drugs and 206 medical devices for cardiovascular diseases.

  25 October 2024 GxP news

  In 2023, Russia registered 56 generic drugs specifically designed to treat cardiovascular diseases, along with 206 essential medical devices for individuals suffering from these conditions. The Deputy Minister of Health of the Russian Federation, Sergei Glagolev, presented this data during a meeting of the State Duma Committee on Health Protection.

• Payments to doctors for cancer alertness will continue through 2027

  25 October 2024 GxP news

  The State Duma adopted a bill to extend inter-budget transfers to health insurance funds in 2027 to address personnel shortages and reward early cancer detection by health workers. “The changes provided for by the bill are aimed at increasing the efficiency of using compulsory medical insurance funds and providing medical care,” the explanatory note to the draft states.